

1 Rhinovirus infection of airway epithelial cells uncovers the non-ciliated subset as a  
2 likely driver of genetic susceptibility to childhood-onset asthma.

3  
4 Sarah Djeddi<sup>ε,1,2,3</sup>, Daniela Fernandez-Salinas<sup>ε,1,2,3,4</sup>, George X. Huang<sup>5,6</sup>, Vitor R. C. Aguiar<sup>1,2,3</sup>,  
5 Chitrasen Mohanty<sup>10</sup>, Christina Kendzioriski<sup>10</sup>, Steven Gazal<sup>7,8</sup>, Joshua Boyce<sup>5,6</sup>, Carole Ober<sup>9</sup>,  
6 James Gern<sup>10,11</sup>, Nora Barrett<sup>5,6</sup>, Maria Gutierrez-Arcelus\*<sup>1,2,3</sup>

7  
8 ε These authors contributed equally to this work.

9 <sup>1</sup>Division of Immunology, Boston Children's Hospital, Boston, MA, USA

10 <sup>2</sup>Department of Pediatrics, Harvard Medical School, Boston, MA, USA

11 <sup>3</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA

12 <sup>4</sup>Licenciatura en Ciencias Genómicas, Instituto de Biotecnología, Universidad Nacional Autónoma  
13 de México (UNAM), Cuernavaca, Morelos, México.

14 <sup>5</sup>Department of Medicine, Harvard Medical School, Boston, MA, USA

15 <sup>6</sup>Jeff and Penny Vinik Center for Allergic Disease Research, Division of Rheumatology,  
16 Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA.

17 <sup>7</sup>Department of Quantitative and Computational Biology, University of Southern California

18 <sup>8</sup>Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California

19 <sup>9</sup>Department of Human Genetics, University of Chicago, Chicago, Ill, USA.

20 <sup>10</sup>Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison,  
21 Madison, WI, USA.

22 <sup>11</sup>Departments of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public  
23 Health, Madison, WI, USA

24  
25 \*Corresponding author:

26  
27 Maria Gutierrez-Arcelus

28 Boston Children's Hospital

29 Division of Immunology

30 Karp Family Research Laboratories, Room 102016.1

31 1 Blackfan Circle

32 Boston, MA, 02115

33 [mgutierr@broadinstitute.org](mailto:mgutierr@broadinstitute.org)

34 857-559-3229

35

36

37

## 38 Abstract

39

40 Asthma is a complex disease caused by genetic and environmental factors. Epidemiological  
41 studies have shown that in children, wheezing during rhinovirus infection (a cause of the common  
42 cold) is associated with asthma development during childhood. This has led scientists to  
43 hypothesize there could be a causal relationship between rhinovirus infection and asthma or that  
44 RV-induced wheezing identifies individuals at increased risk for asthma development. However,  
45 not all children who wheeze when they have a cold develop asthma. Genome-wide association  
46 studies (GWAS) have identified hundreds of genetic variants contributing to asthma  
47 susceptibility, with the vast majority of likely causal variants being non-coding. Integrative  
48 analyses with transcriptomic and epigenomic datasets have indicated that T cells drive asthma  
49 risk, which has been supported by mouse studies. However, the datasets ascertained in these  
50 integrative analyses lack airway epithelial cells. Furthermore, large-scale transcriptomic T cell  
51 studies have not identified the regulatory effects of most non-coding risk variants in asthma  
52 GWAS, indicating there could be additional cell types harboring these “missing regulatory  
53 effects”. Given that airway epithelial cells are the first line of defense against rhinovirus, we  
54 hypothesized they could be mediators of genetic susceptibility to asthma. Here we integrate  
55 GWAS data with transcriptomic datasets of airway epithelial cells subject to stimuli that could  
56 induce activation states relevant to asthma. We demonstrate that epithelial cultures infected  
57 with rhinovirus significantly upregulate childhood-onset asthma-associated genes. We show that  
58 this upregulation occurs specifically in non-ciliated epithelial cells. This enrichment for genes in  
59 asthma risk loci, or ‘asthma heritability enrichment’ is also significant for epithelial genes  
60 upregulated with influenza infection, but not with SARS-CoV-2 infection or cytokine activation.  
61 Additionally, cells from patients with asthma showed a stronger heritability enrichment  
62 compared to cells from healthy individuals. Overall, our results suggest that rhinovirus infection  
63 is an environmental factor that interacts with genetic risk factors through non-ciliated airway  
64 epithelial cells to drive childhood-onset asthma.

## 65 Introduction

66 Asthma is a complex and heterogeneous disease that affects 300 million children and adults  
67 worldwide and represents a significant burden to healthcare (\$82 billion for the US in 2013) <sup>1</sup>. It  
68 is characterized by inflammation of the airways leading to recurrent episodes of airflow  
69 obstruction and symptoms such as wheezing, shortness of breath and coughing. Asthma patients  
70 have impairments of epithelial barrier function, manifested by irregular disruption of the tight  
71 junctions, detachment of ciliated cells and reduced expression of cell-cell adhesion molecules  
72 (for instance, E-cadherin) <sup>2</sup>. This barrier disruption allows environmental substances like  
73 allergens, viruses, bacteria and toxic substances to penetrate the submucosa more easily.  
74 Allergens, viral infections, and type 2 inflammation have been shown to further damage the  
75 barrier integrity of the airway epithelium; moreover, they trigger asthma exacerbations <sup>3</sup>.  
76 Longitudinal epidemiological studies have shown that wheezing caused by rhinovirus infection in  
77 children is a risk factor for developing asthma later in childhood <sup>4-6</sup>. These observations have led  
78 to two hypotheses: (1) rhinovirus infection could be causal in asthma development or (2)  
79 rhinovirus-induced wheeze is a biomarker that identifies children at increased risk for asthma  
80 development. In some children, rhinovirus wheezing does not lead to asthma.

81  
82 Genome-wide association studies (GWAS) have discovered more than 100 risk loci for asthma <sup>7,8</sup>.  
83 Similar to other complex diseases, the vast majority of the likely causal risk variants are non-  
84 coding. As a consequence, deciphering the mechanisms through which the risk alleles lead to  
85 disease is challenging; it has been achieved for only a small minority of risk loci. Using a suite of  
86 recently developed methods that integrate GWAS data with functional genomics datasets,  
87 investigators have discovered key cell types that mediate the genetic susceptibility to complex  
88 diseases. For example, risk variants for rheumatoid arthritis are enriched in regulatory elements  
89 specific for CD4 T cells, and studies in patients and mice have shown the relevance of these cells  
90 in the pathogenesis of this disease <sup>9-13</sup>. Additionally, GWAS integration with transcriptomics  
91 revealed that a significant proportion of the risk alleles for Alzheimer's disease act through the  
92 myeloid lineage rather than the brain <sup>14</sup>. Alzheimer's disease is now considered an immune-

93 mediated disease <sup>14,15</sup>. For asthma, T cell-specific regulatory elements and gene expression are  
94 enriched in genetic risk loci <sup>12,13,16,17</sup>, with some highlighting particularly Th2 cells consistent with  
95 the role of type 2 inflammation in asthma pathogenesis <sup>18–21</sup>.

96  
97 The observations that non-coding risk variants affect gene regulation in cell types relevant to  
98 each disease have motivated large-scale transcriptomic studies to identify genetic variants that  
99 are associated with both gene expression (expression quantitative trait loci, eQTL) and disease  
100 risk. However, only 25-40% of risk variants for immune-mediated diseases co-localize with eQTLs  
101 in immune cells <sup>22–24</sup>. For asthma, alleles at only 47% of loci co-localize with leukocyte expression  
102 and/or splicing QTLs <sup>22</sup>. Hence, the regulatory effects of most non-coding risk variants remain  
103 unknown. More recent studies have highlighted that these “missing regulatory effects” could be  
104 hidden in specific activation or differentiation cell states that haven’t been systematically  
105 ascertained <sup>25–28</sup>.

106  
107 GWAS enrichment studies have been highly biased towards annotations of blood immune cell  
108 types, with reduced resolution when using other tissues relevant to the context of asthma, such  
109 as GTEx tissues from post-mortem human organs <sup>11,13,16,29,30</sup>. Here we sought to define whether  
110 airway epithelial cell states could be driving genetic susceptibility to asthma. We analyzed 10  
111 single-cell and bulk transcriptomic datasets of epithelial cells subject to different activation  
112 conditions. We integrated these datasets with GWAS summary statistics for childhood-onset  
113 asthma (COA), adult-onset asthma (AOA), unspecified-onset asthma (henceforth referred to as  
114 all asthma), and a genetically correlated type 2 inflammation trait: allergy/eczema  
115 (**Supplementary Table 1**) <sup>31–33</sup>. We additionally tested three control traits to assess the specificity  
116 of our findings. We used state of the art methods that control for linkage disequilibrium, take  
117 advantage of most ascertained genetic variants in the genome, and have been shown to work  
118 well for bulk and single cell datasets <sup>13,17</sup>.

## 119 Results

120 We applied two methods that use GWAS data to identify relevant cell types for disease. Linkage  
121 Disequilibrium Score-regression in Specifically Expressed Genes (LDSC-SEG) identifies heritability  
122 enrichment in genomic annotations (such as genes or chromatin marks with specific presence in  
123 a particular cell type or cell state)<sup>13</sup>. Single-cell disease-relevance score (scDRS) identifies cells,  
124 from single-cell RNA-seq data, that significantly express genes in GWAS loci (weighted according  
125 to their strength of association with disease) relative to null sets of control genes in the same  
126 dataset<sup>17</sup>. We retrieved GWAS summary statistics from asthma related traits as described above.  
127 Throughout our analyses we included three complex traits as controls: height, as a non-immune  
128 control, Alzheimer's disease (AD) as a trait implicating myeloid cells, and rheumatoid arthritis  
129 (RA) as a lymphocyte-driven disease with a strong T cell component<sup>11,13,16,17,29</sup>.

130

### 131 T cell validation

132 First, we sought to validate T-cell involvement in the genetic susceptibility to asthma, as  
133 previously reported in the literature<sup>13,16,17,29</sup>. Applying LDSC-SEG to bulk ATAC-seq data of human  
134 peripheral blood leukocyte populations, we confirmed that T-cell specific open chromatin regions  
135 are significantly enriched in heritability for asthma-related traits (**Supplementary Figure 1**)<sup>16</sup>.  
136 Furthermore, when comparing cell types between their resting and activated state, we confirmed  
137 that activation-specific open chromatin in T cells has significant heritability enrichment for all the  
138 asthma-related traits (**Supplementary Figure 1E**). Next, we applied scDRS to single-cell RNA-seq  
139 datasets to identify cells with significant over-expression of risk genes identified from GWAS  
140 studies (see Methods). In sinonasal mucosa tissue from healthy donors and chronic rhinosinusitis  
141 patients, we observed that 21-83% of cells with significant disease relevant score (10% FDR) for  
142 asthma-related traits are T cells (**Supplementary Figure 2**). In a dataset of house dust mite-  
143 activated T cells from asthma and allergic patients, we observed that among the cells with  
144 significant disease relevant score, most were T effector and Th2 cells (51-57% and 48-42%  
145 respectively, **Supplementary Figure 3**). Overall, these analyses confirm the validity of the

146 methods used for this study and confirm previous findings showing the relevance of T cells in the  
147 genetic susceptibility to asthma-related traits.

148

149 **Rhinovirus infection induces upregulation of asthma-associated genes in epithelial cells from**  
150 **healthy donors.** To assess the role that rhinovirus infection could play in asthma genetic  
151 susceptibility at the epithelial cell level, we analyzed a publicly available bulk RNA-seq data of  
152 basal airway epithelial cells from healthy donors (N=9) that were infected in vitro with RV-A16  
153 (rhinovirus species RV-A, subtype 16) or treated with PBS vehicle control (**Figure 1A**)<sup>34</sup>. Using a  
154 linear mixed model, we performed differential expression analysis (DEA) testing for rhinovirus  
155 infection versus PBS vehicle. From the 14,883 tested genes, we selected the top 10% based on t-  
156 statistic (as recommended by LDSC-SEG) to select genes that are upregulated with rhinovirus  
157 infection(**Figure 1B**). We used LDSC-SEG to investigate whether this gene set showed an  
158 enrichment of asthma heritability. Our analysis showed significant heritability enrichment in  
159 rhinovirus-upregulated genes for all asthma (P = 0.033) and COA (P = 0.037), with a larger  
160 coefficient observed for COA (**Figure 1C**). Moreover, we did not observe any significant  
161 enrichment for any of the control traits (AD, RA, height) (**Supplementary Figure 4A**). The fact that  
162 we did not observe significant heritability enrichment in RV-upregulated genes for RA suggests  
163 that the signal observed for all asthma and COA is not due to a general immune transcriptional  
164 response, but rather a response that is specific for RV-infection of epithelial cells.

165

166 Next, we sought to validate these findings in an independent study using a different strain of RV.  
167 We reanalyzed a bulk RNA-seq time course dataset of epithelial cells from 3 healthy donors  
168 where cells were infected with RV-C15, and samples were collected before infection and at 12,  
169 24, and 42 hours post-infection (HPI) (**Figure 1D**)<sup>35</sup>. We performed differential expression  
170 analysis to identify genes upregulated specifically in each time point (versus all others), and  
171 applied LDSC-SEG (**Supplementary Figure 4B**). We observed significant heritability enrichment  
172 for upregulated genes by rhinovirus infection specifically at 24 hours for all asthma-related traits  
173 (P < 0.05, **Figure 1E**). This enrichment was higher for COA and allergy/eczema, compared to all  
174 asthma and AOA (**Figure 1E**). Genes that were specifically expressed at 42 hours post-infection

175 also had positive enrichment for heritability in all traits, but this was only significant for  
176 allergy/eczema ( $P = 0.03$ ). Once again, this enrichment was not present in any of the control traits  
177 (**Supplementary Figure 4C**). Together, these findings suggest that rhinovirus-infected epithelial  
178 cells represent a cell state that may mediate genetic susceptibility to asthma, with a greater  
179 contribution to COA than to AOA.

180

181 **Asthma-associated genes after rhinovirus infection are specifically enriched in non-ciliated**  
182 **epithelial cells.** We then asked whether there were specific epithelial cell subsets that may  
183 mediate asthma genetic risk after rhinovirus infection. To evaluate this, we used single-cell RNA-  
184 seq data of 3 healthy donors, where airway epithelial cell samples were infected with RV-C15 or  
185 resting and profiled at 24 hours (**Figure 2A, Supplementary Figure 5A-C**). We performed cell  
186 clustering and then annotated the clusters based on epithelial cell markers (**Supplementary**  
187 **Figure 5D**). We identified 2 ciliated cell subsets, and 5 non-ciliated cell subsets: basal,  
188 deuterosomal, neuroendocrine, secretory, and transitional (**Figure 2B, Supplementary Figure**  
189 **5D**). We applied scDRS on this dataset to identify cells with significant over-expression of asthma-  
190 associated genes. The number of cells with significant disease relevant scores (10% FDR) varied  
191 per trait: 147 cells for all asthma, 850 cells for COA, 0 for AOA and 147 cells for allergy/eczema  
192 (**Figure 2C**). Notably, COA was the trait with the highest proportion of disease-relevant cells.  
193 Among the cells with a significant disease relevant score, 99% corresponded to the stimulated  
194 condition. Furthermore, the disease relevant cells were strongly over-represented in the non-  
195 ciliated cell subsets, representing 96-99% of the significant cells, while they make up 25% of the  
196 whole dataset (**Figure 2C-D**). As expected, we did not observe any significant cells for height, AD  
197 and RA (**Supplementary Figure 5E**).

198

199 Overall, we identified non-ciliated cells as the main epithelial cell subset with significant  
200 upregulation of childhood-onset asthma-associated genes after rhinovirus infection. However,  
201 only ciliated cells are known to be infected by RV-C15, which we confirmed by looking at the  
202 expression of the RV-15 receptor (*CDHR3*) and the presence of the viral sequence itself in the  
203 scRNA-seq data<sup>36</sup> (**Supplementary Figure 5F-G**). We therefore hypothesized that ciliated cells

204 may communicate with non-ciliated cells upon rhinovirus infection. We used CellphoneDB to  
205 investigate some of the possible ligand-receptor mechanisms through which cells may be  
206 communicating<sup>37</sup>. Specifically, we looked for ligand-encoding genes expressed in ciliated cells  
207 and their corresponding receptor-encoding gene expressed in non-ciliated cells. Furthermore, we  
208 required that the ciliated cell ligand-encoding gene is upregulated upon rhinovirus infection. We  
209 identified a potential pair of interactors consisting of *LGALS9*, which codes for a galectin from the  
210 beta-galactoside-binding protein family implicated in the modulation of the cell-cell and cell-  
211 matrix interactions, and *SORL1*, a gene encoding sortilin-related receptor, which may have a role  
212 in endocytosis and intracellular trafficking (**Supplementary Figure 5H-I**).

213  
214 **Enrichment of asthma-associated genes after rhinovirus infection is strong in epithelial cells**  
215 **from asthma patients.** Having observed the enrichment of asthma-associated genes after RV  
216 infection in both bulk and single-cell level in healthy subjects, we asked whether we would  
217 observe the same enrichment in samples coming from asthma patients. To do this, we repeated  
218 the differential expression analysis between rhinovirus RV-A16 infection and treatment with PBS  
219 from the first dataset<sup>34</sup>, this time using the asthma patient cohort (**Figure 3A**). We found 2,843  
220 differentially expressed genes at 5% FDR, 1,353 of them upregulated and 1,481 downregulated  
221 after RV infection (**Figure 3B**). Of the 2,843 differentially expressed genes in patients, 1,834 were  
222 also differentially expressed in healthy controls. After selecting the top 10% genes by t-statistic  
223 (1,488) and running LDSC-SEG, we observed significant heritability enrichment for all asthma ( $P$   
224 = 0.003) and COA ( $P$  = 0.003, **Figure 3C**). We did not observe heritability enrichment for down-  
225 regulated genes by RV ( $P$  > 0.05, **Supplementary Figure 6C**). While the results were consistent  
226 with what we observed in healthy controls (COA  $\tau^*$ =0.17, all asthma  $\tau^*$ = 0.15), the enrichment  
227 of RV-upregulated asthma-associated genes was more significant and had a larger enrichment  
228 coefficient in the asthma patients (COA  $\tau^*$ =0.32, all asthma  $\tau^*$ =0.25).

229  
230 Based on these results, we hypothesized that asthma patients might have airway epithelial cells  
231 in a transcriptomic state that over-expresses asthma-risk genes in comparison to healthy  
232 controls, which might be linked to or independent of their response to RV. To test this, we



233 analyzed differentially expressed genes between asthma patients and healthy individuals taking  
234 all samples while controlling for RV/PBS treatment. We found 994 differentially expressed genes  
235 between patients and controls (5% FDR, **Figure 3D**). After selecting the top 10% genes  
236 upregulated in patients based on t-statistic (1,593), we found a suggestive significant enrichment  
237 for COA heritability ( $P = 0.05$ , **Figure 3E**). As expected, our control traits did not have any  
238 significant heritability enrichment for either of the annotations tested (**Supplementary Figure 6**).  
239 Overall, these results suggest that the epithelial cells from patients could be in a state that is  
240 over-expressing asthma-associated genes.

241  
242 **Genes at asthma risk loci upregulated with rhinovirus infection in airway epithelial cells.** We  
243 then investigated which of the genes upregulated by rhinovirus infection are associated with COA  
244 and AOA. To do so, we retrieved the GWAS lead variants identified by Ferreira et al.<sup>38</sup>. We then  
245 linked risk variants to genes using three approaches: (1) selecting the likely target genes identified  
246 by the locus-to-gene (L2G) algorithm of Open Targets Genetics, herein called L2G genes, (2)  
247 selecting the closest gene to the lead variant, and (3) selecting genes within a 250kb window of  
248 the lead variant (see Methods). From these gene lists, we selected genes that were upregulated  
249 upon rhinovirus infection in epithelial cells at 5% FDR (**Figure 4**)<sup>34,35</sup>. For COA we identified 55  
250 risk loci with genes upregulated upon rhinovirus infection in epithelial cells, 13 of which have L2G  
251 likely target genes (e.g. *IL1RL1*, *IL4R*, *GSDMB*, *OVOL1*, *MYC*), and 6 are the closest gene to the  
252 lead variant (e.g. *IRF1*, *GPR183*). For AOA only 19 risk loci have genes upregulated by RV in  
253 epithelial cells, among which 3 are likely target genes (e.g. *IL4R*, *HDAC7*, *IL1RL1*) and 3 are the  
254 closest gene to the lead variant (e.g. *RAPGEF3*, *IRF1*, *SSR3*). Few genes were shared between COA  
255 and AOA (*IRF1*, *IL4R*, *PDLIM4*, *IL1R2* and *IL1RL1*).

256  
257 After having characterized the asthma-associated genes that are upregulated in RV-infected  
258 epithelial cells, we sought to define which of these genes are shared with T cells. To do so, we  
259 compared the levels of expression of the genes in the RV-datasets with a dataset we previously  
260 published consisting of 8 activation time points of human periphery memory CD4+ T cells  
261 stimulated with anti-CD3/CD28 microbeads<sup>25</sup>. One of the highlighted genes that also had an

262 increased expression in T cells was *MYC*, with an increase at 2 and 4 hours post-stimulation.  
263 Notably, this gene's expression was not only increased after rhinovirus infection within asthma  
264 patients ( $P=0.01$ ) and within healthy controls ( $P=0.0009$ ) but was also upregulated in patients  
265 compared to controls ( $P=0.01$ ). On the other hand, *OVOL1*, another GWAS gene upregulated in  
266 RV-infected epithelial cells, shows the same pattern of expression as *MYC* in epithelial cells, but  
267 shows almost no expression in T cells (**Figure 4B, Supplementary Figure 7**). *OVOL1* is also  
268 associated with atopic dermatitis, another type 2 inflammatory disease and a recent meta-  
269 analysis study confirmed this susceptibility locus for eczema-associated asthma<sup>39</sup>.

270

### 271 **Other viral infections in epithelial cells and their association with asthma susceptibility.**

272 We next asked whether other viruses could potentially be inducing upregulation of asthma-  
273 associated genes in epithelial cells. First, we analyzed a bulk RNA-seq dataset of bronchial  
274 epithelial cells stimulated by influenza A virus at 48 hours or sham control ( $N = 3$  healthy donors,  
275 **Figure 5A**). We identified differentially expressed genes between influenza A and the sham  
276 control and we selected the top 10% upregulated genes ranked by a t-statistic to run LDSC-SEG  
277 (**Supplementary Figure 8A**). The results show a significant enrichment of heritability for the four  
278 asthma-related traits ( $P < 0.05$ ), suggesting that influenza A infection also significantly  
279 upregulates asthma and allergy-associated genes (**Figure 5B**). We did not observe any significant  
280 enrichment for the control traits (**Supplementary Figure 8B**).

281

282 Subsequently, we analyzed a single-cell RNA-seq dataset of immune and non-immune cells  
283 obtained by nasopharyngeal swabs from COVID-19 patients or healthy donors ( $N=58$ , **Figure 5C-**  
284 **D**)<sup>40</sup>. We identified cells with significant disease-relevant scores at 10% FDR, among which we  
285 found 174 cells for AOA, 795 cells for COA, 594 for allergy/eczema and 280 for all asthma (**Figure**  
286 **5E**). COA yielded the highest number of disease relevant cells. We observed an increase in  
287 proportions of enriched cells for T cells in all traits and for squamous cells in COA, allergy/eczema  
288 and all asthma (**Figure 5F**). More precisely, T cells which represented 5% of the cells in the  
289 dataset, constituted 78% of significant cells for AOA, 11% for COA, 42% for allergy/eczema and  
290 61% for all asthma (**Figure 5F**). The COVID-19 status did not have any significant impact on the

291 asthma-associated expression, as the disease-relevant cells were not overrepresented in any  
292 specific patient group (**Figure 5G**). As expected, we observed an enrichment for the macrophages  
293 cluster in Alzheimer's and T cells cluster in rheumatoid arthritis (**Supplementary Figure 8C**).  
294 Additionally, we analyzed a dataset of bronchial epithelial cells (BECs) infected with SARS-CoV-2  
295 in vitro, and profiled with scRNA-seq after one, two or three days, along with non-infected cells  
296 (N = 1 healthy control, **Supplementary Figure 9A-B**). We clustered and annotated ciliated and  
297 non-ciliated cell subsets, and applied scDRS for the four asthma-related traits (**Supplementary**  
298 **Figure 9C-D**). We identified cells with significant disease-relevant scores at 10% FDR, finding 3  
299 cells for AOA, 802 cells for COA, 243 cells for allergy/eczema and 621 cells for all asthma  
300 (**Supplementary Figure 9D-E**). The disease relevant cells were strongly over-represented in the  
301 non-infected cells subsets, constituting 62-89% of the significant cells (**Supplementary Figure 9F**).  
302 Overall, these findings indicate that the influenza virus significantly induces the expression of  
303 asthma-associated genes, whereas SARS-CoV-2 does not.

304

### 305 **Epithelial cells activated with cytokines relevant for type 2 inflammation.**

306 Both epithelial and immune cells respond to cytokines by upregulating signaling pathways that  
307 drive inflammation. Some pro-inflammatory cytokines relevant to asthma are IL-4, IL-13, IL-17  
308 and interferon (IFN $\gamma$ ). These cytokines are upregulated in subsets of patients with severe or type  
309 2 asthma <sup>41-46</sup>. Moreover, blockade of IL4R $\alpha$  is a highly effective treatment for moderate to  
310 severe asthma <sup>47</sup>. Consequently, we asked whether epithelial cells stimulated with cytokines  
311 might induce a transcriptional program enriched for asthma-associated genes. First we used a  
312 bulk RNA-seq dataset consisting of human bronchial epithelial cells (HBECs) that were stimulated  
313 with either IFN $\alpha$ , IFN $\gamma$ , IL-13 or IL-17 (N = 6 healthy donors, **Figure 6A**) <sup>48</sup>. We selected the top  
314 10% upregulated genes by t-statistic for each stimulus (**Supplementary Figure 10A**). We used  
315 LDSC-SEG to analyze these 4 sets of genes in the 4 asthma-associated traits and the control traits.  
316 We did not identify any significant heritability enrichment for any of the stimuli gene sets for the  
317 asthma-associated traits tested here (**Figure 6B**), nor for the control traits (except for genes  
318 upregulated by IFN $\gamma$  for rheumatoid arthritis, **Supplementary Figure 10B**).

319

320 Next, given that IL-13 might work synergistically with IL-4, we performed bulk RNA-seq of nasal  
321 airway epithelial cells from healthy donors (N = 5) co-stimulated in vitro with IL-4 and IL-13  
322 (**Figure 6C**). We tested DE genes for the IL-4-IL-13 condition compared to the unstimulated  
323 control. In line with the results observed in the previous analysis, we found no significant  
324 enrichment for any of the asthma-associated (**Figure 6D**) or control traits (except for AD,  
325 **Supplementary Figure 10E**). Together, these results suggest that epithelial cells upregulate  
326 asthma-associated genes in a stimulus-specific manner, which to the extent of this study, is not  
327 caused by the stimulation with the cytokines tested here.

328

## 329 Discussion

330 While some genetic risk variants for asthma are enriched near genes with T cell-specific  
331 expression<sup>13,17,22,28</sup>, the effects of most variants on gene regulation remain unknown. In this  
332 study, we asked whether some of these “missing regulatory effects” could be hidden in airway  
333 epithelial cells, given they are the first line of contact for respiratory viruses, including those that  
334 have been associated with asthma development or exacerbations. We analyzed ten  
335 transcriptomic datasets of human airway epithelial cells cultured under different stimuli and  
336 integrated them with genetic susceptibility data for asthma and related traits. We consistently  
337 showed that rhinovirus-activated epithelial cells significantly upregulate genes at childhood-  
338 onset asthma risk loci. We observed this in samples from healthy donors and even more so in  
339 cells from asthma patients. Notably, we discovered that non-ciliated cells are the subset driving  
340 these associations with asthma, indicating that non-ciliated airway epithelial cells activated with  
341 rhinovirus are key mediators of genetic susceptibility to childhood-onset asthma. While other  
342 respiratory viruses, such as influenza might also significantly upregulate genes at asthma risk loci,  
343 this is not likely a general virus response or epithelial cell activation signature, given that we did  
344 not detect asthma heritability enrichment for SARS-CoV-2 or cytokine-upregulated genes.

345

346 Our findings are consistent with epidemiological studies that have shown associations between  
347 wheezing illness caused by rhinovirus infection and asthma development in children<sup>4,49–51</sup>.  
348 Additionally, a previous birth cohort study identified genetic variants at the 17q21 locus that

349 were associated with asthma in children who had rhinovirus-associated wheezing illness in the  
350 first 3 years of life, but not in children who had RSV-associated wheezing illnesses at those same  
351 ages <sup>52</sup>. In that study, rhinovirus upregulated two genes at this locus, *ORMDL3* and *GSDMB*, in  
352 PBMCs <sup>52</sup>. Here, we observe that in non-ciliated airway epithelial cells rhinovirus induces  
353 upregulation of *GSDMB* as well as putative causal genes in 54 additional loci. This demonstrates  
354 a widespread interaction between *in vitro* rhinovirus infection and polygenic susceptibility to  
355 childhood-onset asthma, specifically mediated through airway epithelial cells. These findings are  
356 concordant with a previous study reporting that genes at COA-specific risk loci (as compared to  
357 AOA) have high expression in skin, which is a barrier tissue with an abundance of epithelial cells  
358 <sup>30</sup>. Overall, our findings support the hypothesis that rhinovirus could be causally linked to asthma  
359 development in children and not just be a biomarker of children destined to develop asthma. Not  
360 all children that get RV-wheezing develop asthma, and our findings suggest that the combination  
361 of preschool rhinovirus wheezing illnesses and a high genetic burden synergistically promote the  
362 development of childhood asthma.

363  
364 We discovered that non-ciliated cells (basal, secretory, and transitional) are the specific cell  
365 subsets that overexpress genes at asthma risk loci. This suggests that an important fraction of  
366 the non-coding risk variants for asthma likely affect gene regulation in non-ciliated cells under  
367 specific viral activation states. In our study we looked at two different rhinovirus types. For the  
368 case of RV-C15, the receptor of the virus, CDHR3, is mainly expressed in the ciliated cells <sup>53,54</sup> and  
369 viral RNA quantification confirmed this subset is the one directly infected by the virus  
370 **(Supplementary Figure 5G)**. This suggested that RV-infected ciliated cells efficiently transmit a  
371 signal to the non-ciliated cells, which then express genes in asthma risk loci. The time course  
372 experiments indicated this upregulation of asthma-associated genes occurred predominantly at  
373 24 and 42 hours <sup>35</sup>. In our analyses of RV-A16 infected epithelial cells, the data came from bulk  
374 RNA-seq of basal cells (non-ciliated) treated for 24 hours. In contrast to RV-C15, RV-A16 binds to  
375 the ICAM receptor, which is expressed in ciliated cells and basal cells <sup>55</sup>. Strikingly, while the cell  
376 subsets that get directly infected differ between the two RV strains, both significantly  
377 upregulated asthma-associated genes in non-ciliated cells at 24 hours. By contrast, for SARS-CoV-

378 2, *in vitro* infection did not upregulate genes in asthma risk loci; rather, the non-infected cells  
379 presented a significant expression of asthma-associated genes. Although the data in this study  
380 came from only one individual, the cells with significant disease relevant scores were also  
381 predominantly non-ciliated cells (> 83%, **Supplementary Fig. 9**). Future single-cell studies with  
382 larger sample sizes and ascertaining infection by multiple types of viruses could point to  
383 additional epithelial cell subsets and cell states as candidate drivers of genetic susceptibility to  
384 asthma.

385  
386 The observations in our study may also be relevant to virus-induced asthma exacerbation <sup>56</sup>.  
387 Here, we not only demonstrate that rhinovirus infection induces a transcriptional response  
388 enriched in childhood-onset asthma risk, but we also identified a heritability enrichment for  
389 genes upregulated in asthma patients compared to controls, even when controlling for RV  
390 infection (suggestive P = 0.051, **Figure 3E**). This result goes in line with a previous observation  
391 that, at the open chromatin level, airway epithelial cells of asthma patients have a large amount  
392 of open chromatin regions at baseline that are RV-response regions in healthy controls <sup>34</sup>. It is  
393 possible that over-expression of asthma-associated genes at baseline may increase the risk for  
394 acute virus-induced exacerbations in patients with asthma. Influenza infections, which can cause  
395 asthma exacerbations (especially in adults) <sup>57-59</sup>, induced an enrichment of both adult-onset and  
396 childhood-onset asthma heritability in influenza upregulated genes in airway epithelial cells.  
397 Furthermore, SARS-CoV-2 seems less likely than other viruses to provoke asthma exacerbations,  
398 and asthma does not appear to be a risk factor for severe SARS-CoV-2 infection <sup>60</sup>. This could be  
399 due to multiple reasons, such as allergy-induced reduction in the ACE2 receptor <sup>61</sup>, but it is also  
400 in line with our observations that SARS-CoV-2 infection itself does not induce a transcriptional  
401 program significantly enriched in asthma heritability <sup>61</sup>.

402  
403 Our study had some limitations. We were not able to ascertain all possible epithelial cell subsets  
404 and states. Most of the datasets analyzed involved *in vitro* infections, rather than *in vivo* infected  
405 samples. Additionally, all samples came from adults, which made it all the more striking that we  
406 detected heritability enrichments for childhood-onset asthma. Future studies in children are

407 important to validate these findings. Furthermore, we were limited by the cell sources and  
408 specific time points and experimental designs of each study. In particular, the absence of asthma  
409 heritability enrichment in cytokine-upregulated genes in epithelial cells could imply multiple  
410 scenarios. One possibility could be that even though pro-inflammatory cytokines (IL-4, IL-13,  
411 IFN $\alpha$ , IFN $\gamma$ , IL-17) upregulate many genes in epithelial cells (684-2876 at 5% FDR in our analyses),  
412 they do not significantly interact with polygenic risk factors for asthma in epithelial cells. Other  
413 possibilities for the absence of signal could be that the cytokine-induced activation might interact  
414 with genetic risk factors acting in T cells or other non-epithelial cells, or that there are interactions  
415 with environmental conditions not present in the models included in this analysis.

416  
417 Overall, our findings of asthma heritability enrichment in various epithelial cell states (resting  
418 versus virus-infected, patients versus healthy controls) could reflect variability in how risk  
419 variants contribute to disease onset versus progression. These results highlight the importance  
420 of studying the cellular context in which GWAS loci contribute to disease risk and will ultimately  
421 help to better understand the mechanisms through which those risk variants are acting.  
422 Moreover, the outcomes of our study could open the door to new therapeutic avenues. Indeed,  
423 drug targets that have genetic evidence are more likely to be approved and move forward to  
424 clinical trials than those without it <sup>62</sup>. Large-scale multi-omic studies (with comparable power to  
425 GWAS <sup>63</sup>) of non-ciliated airway epithelial cells activated with rhinovirus could help identify the  
426 target genes of non-coding asthma risk variants, together with functional validations with  
427 approaches such as base editing. Finally, if our observations are confirmed and further  
428 characterized by future studies, it would support the development of a rhinovirus vaccine or  
429 other protective intervention as a way to prevent childhood-onset asthma <sup>64</sup>.

## 430 Material and methods

### 431 Dataset collection

432 We downloaded transcriptomic datasets from the National Center for Biotechnology Information  
433 (NCBI) Gene Expression Omnibus (GEO), Genome Sequence Archive (GSA) and from ImmPORT.



434 We also downloaded a chromatin accessibility dataset (ATAC-seq) from GEO (**Supplementary**  
435 **Table 2**).

<b>Supplementary Table 2. Datasets used in this study.</b>		
<b>Data type</b>	<b>Source</b>	<b>Accession number</b>
ATAC-seq	Calderon et al., 2019	GSE118189
scRNA-seq	Wang et al., 2023	HRA000772 (Genome Sequence Archive)
scRNA-seq	Seumois et al., 2020	GSE146170
RNA-seq	Helling et al., 2020	GSE152550
RNA-seq	Basnet et al., 2023	SDY1882 (ImmPORT)
scRNA-seq	Basnet et al., 2023	SDY1882 (ImmPORT)
RNA-seq	Tao et al., 2022	GSE193164
scRNA-seq	Ravindra et al., 2021	GSE166766
RNA-seq	Koh et al., 2022	GSE185200
RNA-seq	Barret lab	Will be published as part of current study

436

#### 437 **Ethical approval**

438 The Mass General Brigham Institutional Review Board gave ethical approval for the Barrett  
439 dataset.

440

#### 441 **GWAS collection**

442 We downloaded pre-processed summary statistics for the four asthma-associated traits; adult-  
443 onset asthma, childhood-onset asthma, all asthma, allergy/eczema and for those in our control  
444 panel; height, Alzheimer’s disease and rheumatoid arthritis (**Supplementary Table 1**).

445

<b>Supplementary Table 1. Summary statistics used for heritability enrichment analysis.</b>		
	<b>Studied trait</b>	<b>Reference</b>
Asthma-associated traits	Adult-onset asthma	Ferreira et al., Am J Hum Genet, 2019 <sup>38</sup>
	Childhood-onset asthma	Ferreira et al., Am J Hum Genet, 2019 <sup>38</sup>
	Allergy/eczema	UK biobank <sup>65</sup>
	All asthma	UK biobank <sup>65</sup>
Control traits	Height	Lango, et al., Nature, 2010 <sup>66</sup>



	Alzheimer's disease	Lambert, et al., Nat Genet, 2013 <sup>67</sup>
	Rheumatoid arthritis	Okada, et al., Nature, 2014 <sup>68</sup>

446

#### 447 **Summary statistics processing for visualization**

448 We downloaded the childhood-onset asthma and adult-onset asthma<sup>38</sup> summary statistics from  
449 the GWAS catalog. We used the harmonized summary statistics in the GRCh38 version of the  
450 genome. We removed the MHC region (chr6:28510120-33480577).

451

#### 452 **Bulk RNA-seq data processing and quality check**

453 FASTQ files were aligned to the GRCh38 or GRCh37 human genome using STAR (v2.7.9a) with  
454 standard parameters and two-pass mode, or the Salmon tool (v1.5.1). For BAM files generated  
455 with STAR, counts were calculated using RSEM (v1.3.3). We normalized the counts by  
456 transforming them to their  $\log_2(\text{TPM}+1)$  value, where TPM stands for transcripts per million. To  
457 detect outlier samples, we performed principal component analysis on scaled normalized  
458 expression for the top 1000 most variable genes that were expressed in at least 25% of the  
459 samples. For alignment and quantification, we used the ENSEMBL reference annotation release  
460 105 which was downloaded from the ENSEMBL website.

461

#### 462 **Differential expression analyses**

463 Differential gene expression was tested using a linear mixed model, similar to what we did in  
464 Gutierrez-Arcelus et al.<sup>69</sup>. Specifically, we used a likelihood ratio test between two nested models  
465 (*anova* function in R). In these models, gene expression levels ( $\log_2(\text{TPM} + 1)$ ) represent the  
466 dependent variable. "Donor ID" was included as a predictor variable, treated as a random effect.  
467 To compare one condition against the others, we indicated with 1 the tested condition and 0 for  
468 the others (the test variable). We used the function "lmer" from the R package "lme4" to  
469 implement the model. For risk gene visualization in the miami plot, P-values were corrected for  
470 multiple hypothesis testing using the package "qvalue". Differentially expressed genes at 5% FDR  
471 are reported for depicting specific genes in risk loci. After each analysis, we calculated a t-statistic  
472 for each gene to rank them and chose the top 10% as annotations for heritability enrichment

473 analysis (see LDSC-SEG section below). The details of each analysis are divided by dataset and  
474 described in the following section.

475

476 - *Helling Dataset*

477 To assess DE genes between rhinovirus treatment and PBS vehicle control within healthy  
478 individuals, we tested genes that had a normalized count greater than 1 in at least 9 samples  
479 which led to a total of 14,883 genes. The threshold for the minimum number of samples reflected  
480 half of the biological replicates (9/18). In addition to having “donor ID” as a random effect, we  
481 accounted for “sex” as a fixed effect. We repeated this process in asthma patients only, testing  
482 14,888 genes for differential expression between rhinovirus infection and PBS vehicle control. To  
483 find DE genes from asthma patients compared to healthy controls, we took all the samples and  
484 recalculated the number of genes present in at least 9 samples. We tested 15,935 genes and  
485 incorporated “treatment” with either PBS or rhinovirus as a fixed effect covariate in the model,  
486 and tested for disease status (0/1).

487

488 *Tao Dataset*

489 We included 16,031 genes having a normalized count greater than 1 in half of the samples (3/6  
490 samples). We tested for differential expression between influenza treatment and control (sham).

491

492 *Koh Dataset*

493 We tested 14,988 genes, to find differentially expressed genes specific to each condition  
494 compared to all others: IFN $\alpha$ , IFN $\gamma$ , IL-13, and IL-17, respectively. We selected genes having a  
495 normalized count greater than 1 in at least 6 samples. This number reflected the smallest amount  
496 of replicates found across conditions (6/36 samples).

497

498 - *Basnet Dataset*

499 We excluded the resting sample from donor B03 from these analyses (see Methods, Bulk RNA-  
500 seq, QC, and analysis). To obtain differentially expressed gene profiles for each time point, we  
501 performed four separate models in which we tested a single time point against the other two

502 and the resting condition. Our fourth model tested for DE genes in activation conditions versus  
503 the resting state through the same approach. Since we had 3 biological replicates for most time  
504 points, we tested genes with a normalized count greater than 1 in at least (3/11) samples, which  
505 yielded 14,380 genes. This gene set was used for all models.

506

507 - *Barrett Dataset*

508 Air-liquid interface (ALI) cultures were grown from nasal basal epithelial cells from 6 healthy adult  
509 donors. ALIs were allowed to mature for 14 days, then stimulated with 10 ng/mL of IL-4 and 10  
510 ng/mL of IL-13 for an additional 7 days, and then lysed with TCL buffer (Qiagen 1031576) at the  
511 conclusion of the experiment. Lysates were stored at -80C and later submitted to the Broad for  
512 SmartSeq2 low input bulk RNA-seq (38bp paired-end sequencing).

513

514 To obtain genes DE under IL-4 and IL-13 co-stimulation we compared them against the non-  
515 stimulated cells. We tested 13,518 genes that had a normalized count greater than 1 in at least  
516 half of the samples (9/18) samples.

517

#### 518 **ATAC-seq data processing and differential accessibility analysis**

519 We used the 829,942 consensus peaks called by Calderon et al. (peaks were called in each sample  
520 separately, then merged across samples, and then counts were re-calculated for all samples using  
521 the merged peak coordinates). We transformed counts into reads per kilobase per million  
522 (RPKM), then quantile normalized and finally scaled to their  $\log_2(\text{normalized RPKM}+1)$ . To assess  
523 differentially accessible (DA) peaks, we first calculated the mean normalized count per cell type  
524 and then created cell-type accessible sets of peaks. We included a peak in the set if it had a  
525 normalized count greater than the mean of the cell type in at least half of the samples  
526 corresponding to subtypes of that cell type. We tested between 400 and 600 thousand peaks per  
527 cell-type for DA. To do so, we implemented a linear mixed model using the normalized counts as  
528 the response variable, and for the predictor, a bit flag system indicating 1 if the sample belonged  
529 to the tested cell type and 0 for the remaining cells. Peaks were sorted by t-statistic and we took  
530 the top 10% peaks for each cell-type-specific annotation. This process was replicated for a second  
531 selection model, implemented to divide peaks between stimulated and unstimulated categories.

532

### 533 **Single-cell RNA-seq, QC and analysis**

534 FASTQ files from the single-cell RNA-seq dataset from Wang et al., Seumois et al., Basnet et al.,  
535 and Ravindra et al.,<sup>35,70–72</sup> were downloaded as indicated in the “Dataset Collection” section. For  
536 each dataset, we aligned FASTQ files to the human reference human genome GRCh38<sup>73</sup>, using  
537 the GENCODE release 32 with cellranger count (v6.1.2), using default parameters. For Basnet et  
538 al, we added the RV-C15 sequence to the reference genome. Counts were then aggregated using  
539 the cellranger aggr (v6.1.2) function with the default parameters. The subsequent analyses were  
540 done for each of the datasets individually. We discarded cells with less than 500 genes expressed  
541 and cells expressing more than 20% of mitochondrial genes. We normalized raw counts with the  
542 “LogNormalize” method from Seurat package (v4.0.5). We used the normalized counts to  
543 perform a PCA with the 1000 most variable genes. We used the top 20 principal components to  
544 perform dimensionality reduction with UMAP to visualize the data. We identified clusters using  
545 the “FindClusters” function with the Louvain algorithm and a resolution parameter of 0.2, using  
546 the top 20 principal components (PCs). We corrected PCs with Harmony package<sup>74</sup> (v0.1.1) as  
547 indicated as follows, if nothing is indicated, no corrections were applied. For Wang et al., dataset  
548 we corrected for “donor ID” and “tissue”. For Basnet et al., dataset we corrected for “donor ID”  
549 and virus infection. For Ravindra et al., dataset we corrected for virus infection.

550 To identify which cellular type was present in each cell cluster, we used the function  
551 “FindVariableFeatures” (parameter; test.use=wilcox) from Seurat package to identify  
552 differentially expressed genes in each cluster. If immune cells were present in the dataset we  
553 used the tool MCPcounter (v1.2.0) to annotate immune cells<sup>75</sup>. Based on these cellular markers  
554 we annotated the clusters with data from the literature<sup>35,76,77</sup>.

555 For data from Ziegler et al.<sup>40</sup> we used the UMAP coordinates, and the cell annotation originally  
556 published by the authors.

### 557 **LDSC-SEG**

558 State-specific gene sets were generated using the top 10% of the genes tested ranked by t-  
559 statistic for each of our DE analyses. Genes coordinates were mapped from the human genome

560 reference GRCh37 GTF file and formatted into bed files. We repeated this process to generate  
561 control bed files containing all the genes tested for DE in each analysis. Symmetric windows of  
562 100kb were added at each side of the genes using the bedtools (v2.31) “slop” function. For bed  
563 files containing ATAC-seq peaks, this window consisted of 225 bp at each side of the peak, to  
564 represent a similar genomic coverage. LD-Score files were generated using the LDSC pipeline  
565 along with data from HapMap 3 and Phase 3 of the European 1000 Genomes obtained from the  
566 LDSC-repository. The regression was run using the baseline model v1.2. We reported the P values  
567 of regression coefficients, and normalized regression coefficient as per-standardized-annotation  
568 effect sizes  $\tau^*$  as in (Gazal et al. 2017 Nat Genet)<sup>78</sup> to allow for multi-trait comparisons.  
569 Regression P values were corrected using the “p.adjust” function from R using both FDR and  
570 bonferroni methods. The reference GTF file used to map the genes was obtained from GENCODE  
571 (v37).

572

### 573 **MAGMA and scDRS**

574 We used the adult-onset asthma, the childhood-onset asthma, the allergy/eczema, the all-  
575 asthma, the rheumatoid arthritis, and the Alzheimer’s GWAS summary statistics as well as the  
576 corresponding set of 1000 putative disease genes (obtained with MAGMA) provided in the  
577 original publication of the scDRS method<sup>17,79</sup>.

578 We used MAGMA (v1.10) to compute the gene-level association P-values and z-scores from  
579 GWAS summary statistics of Height. We transformed P-values to z-scores using this formula:  
580  $2 * pnorm(abs(zscore), mean = 0, sd = 1, lower.tail = F)$  in R. To map SNPs to genes, we used magma  
581 with default parameters specified in the scDRS documentation. We retrieved the top 1000 genes  
582 based on MAGMA z-score as putative disease genes.

583

584 We used scDRS (v1.0.2) to quantify the expression of the putative disease genes derived from  
585 GWAS summary statistics using MAGMA in each cell of each single-cell RNA-seq dataset  
586 separately for the 8 GWAS tested and described previously (Table dataset). We used the function  
587 scDRS “compute-score” with default parameters (--flag-filter-data False).

588

## 589 **Cell-cell interaction between ciliated epithelial cells and non-ciliated epithelial cells**

590 To identify potential pairs of interactors between ciliated and non-ciliated epithelial cells we used  
591 the dataset of Basnet et al. <sup>35</sup>. We first evaluated which genes were differentially expressed  
592 between rhinovirus infected epithelial cells and non-ciliated non-infected epithelial cells. We  
593 identified the hypothetical pair of interactors (ligand-receptor) between ciliated and non-ciliated  
594 cells with CellPhoneDB (v3.1.0) with the method “deg\_analysis”, using the list of differentially  
595 expressed genes defined before and the default parameter. We filtered the results by identifying  
596 the ligand being expressed in ciliated cells and a receptor expressed in non-ciliated cells.

597

## 598 **Linking variants to genes**

599 For the Miami plot we used three different and complementary approaches to map variants to  
600 genes. First, we used data from Open Target Genetics website <sup>80</sup>. We queried the website to  
601 retrieve information for childhood-onset asthma (GCST007995) and adult-onset asthma  
602 (GCST007799). We then extracted the L2G gene and the Closest Gene for each variant when  
603 information was available. We also added a window of 250kb around each variant with the  
604 “bedtools slop” function and retrieved the genes falling in those regions with the “bedtools  
605 intersect” function. Finally, we obtained the intersect between this “snp-to-gene” list of genes  
606 and the genes upregulated upon rhinovirus infection (genes annotated on **Figure 4A**).

607

608 We also retrieved the lead variants from the original paper from Ferreira et al. <sup>38</sup>. We added a  
609 window of 250kb around each variant with the “bedtools slop” function and retrieved the genes  
610 falling in those regions with the “bedtools intersect” function. We identified the closest gene to  
611 the variant by using the function “bedclosest”.

612

## 613 **Software description (Plots, R, and Biorender)**

614 All the plots were generated with R and graphic schematics were generated with Biorender.

615

## 616 **Data availability**

617 Bulk RNA-seq data on dataset with IL-4 and IL-13 activation of airway epithelial cells will be made  
618 available in GEO and dbGAP. Other datasets used are publicly available (details in **Supplementary**  
619 **Table 1**).

## 620 Acknowledgements

621 This study was supported by U19AI095219. CO was supported by U19AI162310. NAB was  
622 supported by AI134989 and U19AI095219. JG and NAB were supported by AACRC RNA  
623 Sequencing Core for Airway Epithelial Cells. MGA was supported by P30AR070253. We thank  
624 Donata Vercelli, Luis Barrera, Peter Nigrovic and his laboratory, and the Gutierrez-Arcelus  
625 laboratory for feedback on this study.

## 626 Conflict of Interest Statement

627 JAB has served on scientific advisory boards for Siolta Therapeutics, Third Harmonic Bio,  
628 Sanofi/Aventis. NAB has served on scientific advisory boards for Regeneron. The rest of the  
629 authors declare that they have no relevant conflicts of interest.

630

## 631 References

632

- 633 1. Porsbjerg, C., Melén, E., Lehtimäki, L., and Shaw, D. (2023). Asthma. *Lancet* *401*, 858–873.
- 634 2. Heijink, I.H., Kuchibhotla, V.N.S., Roffel, M.P., Maes, T., Knight, D.A., Sayers, I., and Nawijn, M.C.  
635 (2020). Epithelial cell dysfunction, a major driver of asthma development. *Allergy* *75*, 1902–1917.
- 636 3. Hellings, P.W., and Steelant, B. (2020). Epithelial barriers in allergy and asthma. *J. Allergy Clin.*  
637 *Immunol.* *145*, 1499–1509.
- 638 4. Jackson, D.J., and Gern, J.E. (2022). Rhinovirus Infections and Their Roles in Asthma: Etiology and  
639 Exacerbations. *J. Allergy Clin. Immunol. Pract.* *10*, 673–681.
- 640 5. Holgate, S.T., Wenzel, S., Postma, D.S., Weiss, S.T., Renz, H., and Sly, P.D. (2015). Asthma. *Nat Rev*  
641 *Dis Primers* *1*, 15025.
- 642 6. Loxham, M., and Davies, D.E. (2017). Phenotypic and genetic aspects of epithelial barrier function  
643 in asthmatic patients. *J. Allergy Clin. Immunol.* *139*, 1736–1751.
- 644 7. Kim, K.W., and Ober, C. (2019). Lessons Learned From GWAS of Asthma. *Allergy Asthma Immunol.*  
645 *Res.* *11*, 170–187.

- 646 8. Vicente, C.T., Revez, J.A., and Ferreira, M.A.R. (2017). Lessons from ten years of genome-wide  
647 association studies of asthma. *Clin Transl Immunology* 6, e165.
- 648 9. Banerjee, S., Webber, C., and Poole, A.R. (1992). The induction of arthritis in mice by the cartilage  
649 proteoglycan aggrecan: roles of CD4+ and CD8+ T cells. *Cell. Immunol.* 144, 347–357.
- 650 10. Kobezda, T., Ghassemi-Nejad, S., Mikecz, K., Glant, T.T., and Szekanecz, Z. (2014). Of mice and men:  
651 how animal models advance our understanding of T-cell function in RA. *Nat. Rev. Rheumatol.* 10,  
652 160–170.
- 653 11. Trynka, G., Sandor, C., Han, B., Xu, H., Stranger, B.E., Liu, X.S., and Raychaudhuri, S. (2013).  
654 Chromatin marks identify critical cell types for fine mapping complex trait variants. *Nat. Genet.* 45,  
655 124–130.
- 656 12. Finucane, H.K., Bulik-Sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P.-R., Anttila, V., Xu, H.,  
657 Zang, C., Farh, K., et al. (2015). Partitioning heritability by functional annotation using genome-  
658 wide association summary statistics. *Nat. Genet.* 47, 1228–1235.
- 659 13. Finucane, H.K., Reshef, Y.A., Anttila, V., Slowikowski, K., Gusev, A., Byrnes, A., Gazal, S., Loh, P.-R.,  
660 Lareau, C., Shores, N., et al. (2018). Heritability enrichment of specifically expressed genes  
661 identifies disease-relevant tissues and cell types. *Nat. Genet.* 50, 621–629.
- 662 14. Gjoneska, E., Pfenning, A.R., Mathys, H., Quon, G., Kundaje, A., Tsai, L.-H., and Kellis, M. (2015).  
663 Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease.  
664 *Nature* 518, 365–369.
- 665 15. Bettcher, B.M., Tansey, M.G., Dorothée, G., and Heneka, M.T. (2021). Peripheral and central  
666 immune system crosstalk in Alzheimer disease - a research prospectus. *Nat. Rev. Neurol.* 17, 689–  
667 701.
- 668 16. Calderon, D., Nguyen, M.L.T., Mezger, A., Kathiria, A., Müller, F., Nguyen, V., Lescano, N., Wu, B.,  
669 Trombetta, J., Ribado, J.V., et al. (2019). Landscape of stimulation-responsive chromatin across  
670 diverse human immune cells. *Nat. Genet.* 51, 1494–1505.
- 671 17. Zhang, M.J., Hou, K., Dey, K.K., Sakaue, S., Jagadeesh, K.A., Weinand, K., Taychameekitchai, A.,  
672 Rao, P., Pisco, A.O., Zou, J., et al. (2022). Polygenic enrichment distinguishes disease associations of  
673 individual cells in single-cell RNA-seq data. *Nat. Genet.*, 1–9.
- 674 18. Robinson, D.S., Hamid, Q., Ying, S., Tscopoulos, A., Barkans, J., Bentley, A.M., Corrigan, C., Durham,  
675 S.R., and Kay, A.B. (1992). Predominant TH2-like bronchoalveolar T-lymphocyte population in  
676 atopic asthma. *N. Engl. J. Med.* 326, 298–304.
- 677 19. Fahy, J.V. (2015). Type 2 inflammation in asthma--present in most, absent in many. *Nat. Rev.*  
678 *Immunol.* 15, 57–65.
- 679 20. Augustine, T., Al-Aghbar, M.A., Al-Kowari, M., Espino-Guarch, M., and van Panhuys, N. (2022).  
680 Asthma and the Missing Heritability Problem: Necessity for Multiomics Approaches in Determining  
681 Accurate Risk Profiles. *Front. Immunol.* 13, 822324.



- 682 21. Busse, W.W., and Viswanathan, R. (2022). What has been learned by cytokine targeting of asthma?  
683 *J. Allergy Clin. Immunol.* *150*, 235–249.
- 684 22. Mu, Z., Wei, W., Fair, B., Miao, J., Zhu, P., and Li, Y.I. (2021). The impact of cell type and context-  
685 dependent regulatory variants on human immune traits. *Genome Biol.* *22*, 122.
- 686 23. Chun, S., Casparino, A., Patsopoulos, N.A., Croteau-Chonka, D.C., Raby, B.A., De Jager, P.L.,  
687 Sunyaev, S.R., and Cotsapas, C. (2017). Limited statistical evidence for shared genetic effects of  
688 eQTLs and autoimmune-disease-associated loci in three major immune-cell types. *Nat. Genet.* *49*,  
689 600–605.
- 690 24. GTEx Consortium, Laboratory, Data Analysis & Coordinating Center (LDACC)—Analysis Working  
691 Group, Statistical Methods groups—Analysis Working Group, Enhancing GTEx (eGTEx) groups, NIH  
692 Common Fund, NIH/NCI, NIH/NHGRI, NIH/NIMH, NIH/NIDA, Biospecimen Collection Source Site—  
693 NDRI, et al. (2017). Genetic effects on gene expression across human tissues. *Nature* *550*, 204–213.
- 694 25. Gutierrez-Arcelus, M., Baglaenko, Y., Arora, J., Hannes, S., Luo, Y., Amariuta, T., Teslovich, N., Rao,  
695 D.A., Ermann, J., Jonsson, A.H., et al. (2020). Allele-specific expression changes dynamically during  
696 T cell activation in HLA and other autoimmune loci. *Nat. Genet.* *52*, 247–253.
- 697 26. Elorbany, R., Popp, J.M., Rhodes, K., Strober, B.J., Barr, K., Qi, G., Gilad, Y., and Battle, A. (2022).  
698 Single-cell sequencing reveals lineage-specific dynamic genetic regulation of gene expression  
699 during human cardiomyocyte differentiation. *PLoS Genet.* *18*, e1009666.
- 700 27. Umans, B.D., Battle, A., and Gilad, Y. (2021). Where Are the Disease-Associated eQTLs? *Trends*  
701 *Genet.* *37*, 109–124.
- 702 28. Soskic, B., Cano-Gamez, E., Smyth, D.J., Ambridge, K., Ke, Z., Matte, J.C., Bossini-Castillo, L.,  
703 Kaplanis, J., Ramirez-Navarro, L., Lorenc, A., et al. (2022). Immune disease risk variants regulate  
704 gene expression dynamics during CD4+ T cell activation. *Nat. Genet.* *54*, 817–826.
- 705 29. Soskic, B., Cano-Gamez, E., Smyth, D.J., Rowan, W.C., Nakic, N., Esparza-Gordillo, J., Bossini-Castillo,  
706 L., Tough, D.F., Larminie, C.G.C., Bronson, P.G., et al. (2019). Chromatin activity at GWAS loci  
707 identifies T cell states driving complex immune diseases. *Nat. Genet.* *51*, 1486–1493.
- 708 30. Pividori, M., Schoettler, N., Nicolae, D.L., Ober, C., and Im, H.K. (2019). Shared and distinct genetic  
709 risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide  
710 studies. *Lancet Respir Med* *7*, 509–522.
- 711 31. Zhu, Z., Lee, P.H., Chaffin, M.D., Chung, W., Loh, P.-R., Lu, Q., Christiani, D.C., and Liang, L. (2018). A  
712 genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of  
713 asthma and allergic diseases. *Nat. Genet.* *50*, 857–864.
- 714 32. Guibas, G.V., Mathioudakis, A.G., Tsoumani, M., and Tsabouri, S. (2017). Relationship of Allergy  
715 with Asthma: There Are More Than the Allergy “Eggs” in the Asthma “Basket.” *Front Pediatr* *5*, 92.
- 716 33. Khan, A.H., Gouia, I., Kamat, S., Johnson, R., Small, M., and Siddall, J. (2023). Prevalence and  
717 Severity Distribution of Type 2 Inflammation-Related Comorbidities Among Patients with Asthma,  
718 Chronic Rhinosinusitis with Nasal Polyps, and Atopic Dermatitis. *Lung* *201*, 57–63.


- 719 34. Helling, B.A., Sobreira, D.R., Hansen, G.T., Sakabe, N.J., Luo, K., Billstrand, C., Laxman, B., Nicolae,  
720 R.I., Nicolae, D.L., Bochkov, Y.A., et al. (2020). Altered transcriptional and chromatin responses to  
721 rhinovirus in bronchial epithelial cells from adults with asthma. *Commun Biol* 3, 678.
- 722 35. Basnet, S., Mohanty, C., Bochkov, Y.A., Brockman-Schneider, R.A., Kendzioriski, C., and Gern, J.E.  
723 (2023). Rhinovirus C Causes Heterogeneous Infection and Gene Expression in Airway Epithelial Cell  
724 Subsets. *Mucosal Immunol.* 10.1016/j.mucimm.2023.01.008.
- 725 36. Bochkov, Y.A., Watters, K., Ashraf, S., Griggs, T.F., Devries, M.K., Jackson, D.J., Palmenberg, A.C.,  
726 and Gern, J.E. (2015). Cadherin-related family member 3, a childhood asthma susceptibility gene  
727 product, mediates rhinovirus C binding and replication. *Proc. Natl. Acad. Sci. U. S. A.* 112, 5485–  
728 5490.
- 729 37. Efremova, M., Vento-Tormo, M., Teichmann, S.A., and Vento-Tormo, R. (2020). CellPhoneDB:  
730 inferring cell-cell communication from combined expression of multi-subunit ligand-receptor  
731 complexes. *Nat. Protoc.* 15, 1484–1506.
- 732 38. Ferreira, M.A.R., Mathur, R., Vonk, J.M., Szwajda, A., Brumpton, B., Granell, R., Brew, B.K., Ullemar,  
733 V., Lu, Y., Jiang, Y., et al. (2019). Genetic Architectures of Childhood- and Adult-Onset Asthma Are  
734 Partly Distinct. *Am. J. Hum. Genet.* 104, 665–684.
- 735 39. Esparza-Gordillo, J., Weidinger, S., Fölster-Holst, R., Bauerfeind, A., Ruschendorf, F., Patone, G.,  
736 Rohde, K., Marenholz, I., Schulz, F., Kerscher, T., et al. (2009). A common variant on chromosome  
737 11q13 is associated with atopic dermatitis. *Nat. Genet.* 41, 596–601.
- 738 40. Ziegler, C.G.K., Miao, V.N., Owings, A.H., Navia, A.W., Tang, Y., Bromley, J.D., Lotfy, P., Sloan, M.,  
739 Laird, H., Williams, H.B., et al. (2021). Impaired local intrinsic immunity to SARS-CoV-2 infection in  
740 severe COVID-19. *Cell* 184, 4713-4733.e22.
- 741 41. Lambrecht, B.N., Hammad, H., and Fahy, J.V. (2019). The Cytokines of Asthma. *Immunity* 50, 975–  
742 991.
- 743 42. Hammad, H., and Lambrecht, B.N. (2021). The basic immunology of asthma. *Cell* 184, 1469–1485.
- 744 43. Camiolo, M.J., Zhou, X., Oriss, T.B., Yan, Q., Gorry, M., Horne, W., Trudeau, J.B., Scholl, K., Chen, W.,  
745 Kolls, J.K., et al. (2021). High-dimensional profiling clusters asthma severity by lymphoid and non-  
746 lymphoid status. *Cell Rep.* 35, 108974.
- 747 44. Woodruff, P.G., Boushey, H.A., Dolganov, G.M., Barker, C.S., Yang, Y.H., Donnelly, S., Ellwanger, A.,  
748 Sidhu, S.S., Dao-Pick, T.P., Pantoja, C., et al. (2007). Genome-wide profiling identifies epithelial cell  
749 genes associated with asthma and with treatment response to corticosteroids. *Proc. Natl. Acad.*  
750 *Sci. U. S. A.* 104, 15858–15863.
- 751 45. Woodruff, P.G., Modrek, B., Choy, D.F., Jia, G., Abbas, A.R., Ellwanger, A., Koth, L.L., Arron, J.R., and  
752 Fahy, J.V. (2009). T-helper type 2-driven inflammation defines major subphenotypes of asthma.  
753 *Am. J. Respir. Crit. Care Med.* 180, 388–395.
- 754 46. Krishnamoorthy, N., Douda, D.N., Brüggemann, T.R., Ricklefs, I., Duvall, M.G., Abdulnour, R.-E.E.,  
755 Martinod, K., Tavares, L., Wang, X., Cernadas, M., et al. (2018). Neutrophil cytoplasts induce TH17

- 756 differentiation and skew inflammation toward neutrophilia in severe asthma. *Sci Immunol* 3.  
757 10.1126/sciimmunol.aao4747.
- 758 47. Castro, M., Corren, J., Pavord, I.D., Maspero, J., Wenzel, S., Rabe, K.F., Busse, W.W., Ford, L., Sher,  
759 L., FitzGerald, J.M., et al. (2018). Dupilumab Efficacy and Safety in Moderate-to-Severe  
760 Uncontrolled Asthma. *N. Engl. J. Med.* 378, 2486–2496.
- 761 48. Koh, K.D., Bonser, L.R., Eckalbar, W.L., Yizhar-Barnea, O., Shen, J., Zeng, X., Hargett, K.L., Sun, D.I.,  
762 Zlock, L.T., Finkbeiner, W.E., et al. (2023). Genomic characterization and therapeutic utilization of  
763 IL-13-responsive sequences in asthma. *Cell Genom* 3, 100229.
- 764 49. Rubner, F.J., Jackson, D.J., Evans, M.D., Gangnon, R.E., Tisler, C.J., Pappas, T.E., Gern, J.E., and  
765 Lemanske, R.F., Jr (2017). Early life rhinovirus wheezing, allergic sensitization, and asthma risk at  
766 adolescence. *J. Allergy Clin. Immunol.* 139, 501–507.
- 767 50. Jarthi, T., and Gern, J.E. (2011). Rhinovirus-associated wheeze during infancy and asthma  
768 development. *Curr. Respir. Med. Rev.* 7, 160–166.
- 769 51. Bønnelykke, K., Sleiman, P., Nielsen, K., Kreiner-Møller, E., Mercader, J.M., Belgrave, D., den  
770 Dekker, H.T., Husby, A., Sevelsted, A., Faura-Tellez, G., et al. (2013). A genome-wide association  
771 study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe  
772 exacerbations. *Nat. Genet.* 46, 51–55.
- 773 52. Calışkan, M., Bochkov, Y.A., Kreiner-Møller, E., Bønnelykke, K., Stein, M.M., Du, G., Bisgaard, H.,  
774 Jackson, D.J., Gern, J.E., Lemanske, R.F., Jr, et al. (2013). Rhinovirus wheezing illness and genetic  
775 risk of childhood-onset asthma. *N. Engl. J. Med.* 368, 1398–1407.
- 776 53. Basnet, S., Bochkov, Y.A., Brockman-Schneider, R.A., Kuipers, I., Aesif, S.W., Jackson, D.J.,  
777 Lemanske, R.F., Jr, Ober, C., Palmenberg, A.C., and Gern, J.E. (2019). CDHR3 Asthma-Risk Genotype  
778 Affects Susceptibility of Airway Epithelium to Rhinovirus C Infections. *Am. J. Respir. Cell Mol. Biol.*  
779 61, 450–458.
- 780 54. Griggs, T.F., Bochkov, Y.A., Basnet, S., Pasic, T.R., Brockman-Schneider, R.A., Palmenberg, A.C., and  
781 Gern, J.E. (2017). Rhinovirus C targets ciliated airway epithelial cells. *Respir. Res.* 18, 84.
- 782 55. Zhou, X., Zhu, L., Lizarraga, R., and Chen, Y. (2017). Human Airway Epithelial Cells Direct Significant  
783 Rhinovirus Replication in Monocytic Cells by Enhancing ICAM1 Expression. *Am. J. Respir. Cell Mol.*  
784 *Biol.* 57, 216–225.
- 785 56. Hammond, C., Kurten, M., and Kennedy, J.L. (2015). Rhinovirus and asthma: a storied history of  
786 incompatibility. *Curr. Allergy Asthma Rep.* 15, 502.
- 787 57. Veerapandian, R., Snyder, J.D., and Samarasinghe, A.E. (2018). Influenza in Asthmatics: For Better  
788 or for Worse? *Front. Immunol.* 9, 1843.
- 789 58. Hasegawa, S., Hirano, R., Hashimoto, K., Haneda, Y., Shirabe, K., and Ichiyama, T. (2011).  
790 Characteristics of atopic children with pandemic H1N1 influenza viral infection: pandemic H1N1  
791 influenza reveals “occult” asthma of childhood. *Pediatr. Allergy Immunol.* 22, e119-23.

- 792 59. Obuchi, M., Adachi, Y., Takizawa, T., and Sata, T. (2013). Influenza A(H1N1)pdm09 virus and  
793 asthma. *Front. Microbiol.* 4, 307.
- 794 60. Sunjaya, A.P., Allida, S.M., Di Tanna, G.L., and Jenkins, C. (2022). Asthma and risk of infection,  
795 hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis.  
796 *J. Asthma* 59, 866–879.
- 797 61. Jackson, D.J., Busse, W.W., Bacharier, L.B., Kattan, M., O’Connor, G.T., Wood, R.A., Visness, C.M.,  
798 Durham, S.R., Larson, D., Esnault, S., et al. (2020). Association of respiratory allergy, asthma, and  
799 expression of the SARS-CoV-2 receptor ACE2. *J. Allergy Clin. Immunol.* 146, 203-206.e3.
- 800 62. Ochoa, D., Karim, M., Ghousaini, M., Hulcoop, D.G., McDonagh, E.M., and Dunham, I. (2022).  
801 Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. *Nat. Rev. Drug*  
802 *Discov.* 21, 551.
- 803 63. Mostafavi, H., Spence, J.P., Naqvi, S., and Pritchard, J.K. (2023). Systematic differences in discovery  
804 of genetic effects on gene expression and complex traits. *Nat. Genet.* 55, 1866–1875.
- 805 64. Stone, C.A., Jr, and Miller, E.K. (2016). Understanding the Association of Human Rhinovirus with  
806 Asthma. *Clin. Vaccine Immunol.* 23, 6–10.
- 807 65. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J.,  
808 Landray, M., et al. (2015). UK biobank: an open access resource for identifying the causes of a wide  
809 range of complex diseases of middle and old age. *PLoS Med.* 12, e1001779.
- 810 66. Lango Allen, H., Estrada, K., Lettre, G., Berndt, S.I., Weedon, M.N., Rivadeneira, F., Willer, C.J.,  
811 Jackson, A.U., Vedantam, S., Raychaudhuri, S., et al. (2010). Hundreds of variants clustered in  
812 genomic loci and biological pathways affect human height. *Nature* 467, 832–838.
- 813 67. Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., DeStafano, A.L.,  
814 Bis, J.C., Beecham, G.W., Grenier-Boley, B., et al. (2013). Meta-analysis of 74,046 individuals  
815 identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat. Genet.* 45, 1452–1458.
- 816 68. Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Kochi, Y., Ohmura, K., Suzuki, A., Yoshida,  
817 S., et al. (2014). Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature*  
818 *506*, 376–381.
- 819 69. Gutierrez-Arcelus, M., Teslovich, N., Mola, A.R., Polidoro, R.B., Nathan, A., Kim, H., Hannes, S.,  
820 Slowikowski, K., Watts, G.F.M., Korsunsky, I., et al. (2019). Lymphocyte innateness defined by  
821 transcriptional states reflects a balance between proliferation and effector functions. *Nat.*  
822 *Commun.* 10, 687.
- 823 70. Wang, W., Xu, Y., Wang, L., Zhu, Z., Aodeng, S., Chen, H., Cai, M., Huang, Z., Han, J., Wang, L., et al.  
824 (2022). Single-cell profiling identifies mechanisms of inflammatory heterogeneity in chronic  
825 rhinosinusitis. *Nat. Immunol.* 23, 1484–1494.
- 826 71. Seumois, G., Ramírez-Suástegui, C., Schmiedel, B.J., Liang, S., Peters, B., Sette, A., and Vijayanand,  
827 P. (2020). Single-cell transcriptomic analysis of allergen-specific T cells in allergy and asthma. *Sci*  
828 *Immunol* 5. 10.1126/sciimmunol.aba6087.


- 829 72. Ravindra, N.G., Alfajaro, M.M., Gasque, V., Huston, N.C., Wan, H., Szigeti-Buck, K., Yasumoto, Y.,  
830 Greaney, A.M., Habet, V., Chow, R.D., et al. (2021). Single-cell longitudinal analysis of SARS-CoV-2  
831 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell  
832 state changes. *PLoS Biol.* *19*, e3001143.
- 833 73. Frankish, A., Diekhans, M., Ferreira, A.-M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J.M., Sisu,  
834 C., Wright, J., Armstrong, J., et al. (2019). GENCODE reference annotation for the human and  
835 mouse genomes. *Nucleic Acids Res.* *47*, D766–D773.
- 836 74. Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M.,  
837 Loh, P.-R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data  
838 with Harmony. *Nat. Methods* *16*, 1289–1296.
- 839 75. Becht, E., Giraldo, N.A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P.,  
840 Sautès-Fridman, C., Fridman, W.H., et al. (2016). Estimating the population abundance of tissue-  
841 infiltrating immune and stromal cell populations using gene expression. *Genome Biol.* *17*, 218.
- 842 76. Hewitt, R.J., and Lloyd, C.M. (2021). Regulation of immune responses by the airway epithelial cell  
843 landscape. *Nat. Rev. Immunol.* *21*, 347–362.
- 844 77. Ordovas-Montanes, J., Dwyer, D.F., Nyquist, S.K., Buchheit, K.M., Vukovic, M., Deb, C., Wadsworth,  
845 M.H., 2nd, Hughes, T.K., Kazer, S.W., Yoshimoto, E., et al. (2018). Allergic inflammatory memory in  
846 human respiratory epithelial progenitor cells. *Nature* *560*, 649–654.
- 847 78. Gazal, S., Finucane, H.K., Furlotte, N.A., Loh, P.-R., Palamara, P.F., Liu, X., Schoech, A., Bulik-Sullivan,  
848 B., Neale, B.M., Gusev, A., et al. (2017). Linkage disequilibrium–dependent architecture of human  
849 complex traits shows action of negative selection. *Nat. Genet.* *49*, 1421–1427.
- 850 79. de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: generalized gene-set  
851 analysis of GWAS data. *PLoS Comput. Biol.* *11*, e1004219.
- 852 80. Ghoussaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E.M., Hercules, A., Fumis, L.,  
853 Miranda, A., Carvalho-Silva, D., Buniello, A., et al. (2021). Open Targets Genetics: systematic  
854 identification of trait-associated genes using large-scale genetics and functional genomics. *Nucleic  
855 Acids Res.* *49*, D1311–D1320.

# Graphical abstract





**Figure 1**



**Figure 1. Bronchial epithelial cells infected with rhinovirus upregulate genes associated with asthma susceptibility.**

**(A)** Experimental design of the *Helling et al.* dataset consisting of basal bronchial epithelial cells from healthy donors stimulated with PBS or RV-A16.


**(B)** Volcano plot showing differentially expressed genes after rhinovirus infection, genes selected based on t-statistic are colored in purple.

**(C)** Bar plot showing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for each of the asthma-associated GWAS studies. Error bars represent  $\tau^* \pm$  standard error. Asterisk denotes  $P < 0.05$  and NS denotes nonsignificant ( $P > 0.05$ ).

**(D)** Experimental design of the Basnet et al. time course dataset consisting of BECs stimulated with RV-C15.

**(E)** Bar plot showing LDSC-SEG heritability enrichment coefficient ( $t^*$ ) for differentially expressed genes at each time point when compared against all others. Error bars represent  $t^* \pm$  standard error. Asterisks denote significance as \*  $P < 0.05$ , \*\*\* Bonferroni-adjusted  $P < 0.05$  and NS denotes nonsignificant ( $P > 0.05$ ).

# Figure 2



**Figure 2. scRNA-seq uncovers non-ciliated epithelial cells as potential mediators for asthma risk.**

**(A)** Experimental design of the *Basnet et al.* scRNA-seq dataset of BECs from healthy donors infected with RV-C15.


**(B)** UMAP visualization of the 10,721 airway epithelial cells colored by cell type.

**(C)** scDRS results represented on the UMAP for the 4 asthma-associated GWAS tested. The intensity of the color represents the disease relevant score, the lighter purple represents a less intense score whereas a more intense purple represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.

**(D)** Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in COA, Allergy/Eczema, All asthma. AOA is not represented on this barplot because no cells were significant.



**Figure 3**



**Figure 3. RV-infected BECs from asthma patients showed a stronger enrichment for asthma risk compared to those of healthy individuals.**

**(A)** Experimental design of *Helling et al.* dataset consisting of BECs from asthma patients stimulated with PBS or RV-A16.

**(B)** Volcano plot showing differentially expressed genes after rhinovirus infection in patient samples. Genes upregulated after infection were selected based on t-statistic and are colored in burgundy.


**(C)** Bar plot showing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) across GWAS studies. Error bars represent  $\tau^* \pm$  standard error. Asterisks denote significance as \*\*\* Bonferroni-adjusted  $P < 0.05$  and NS denotes nonsignificant ( $P > 0.05$ ).

**(D)** Volcano plot showing differentially expressed genes between asthma patients and healthy donors. Genes upregulated in patients were selected based on t-statistic and are colored in blue.


**(E)** Bar plot of LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ), suggestively significant enrichment is labeled. Error bars represent  $\tau^* \pm$  standard error. NS denotes nonsignificant ( $P > 0.05$ ).

Figure 4

A



B  
 bioRxiv preprint doi: <https://doi.org/10.1101/2024.02.02.24302068>; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




**Figure 4. Rhinovirus induced genes that are found in COA and AOA GWAS.**

**(A)** Miami plot of COA and AOA GWAS. Each gray dot shows the SNP found in the *Ferreira et al.*, GWAS. The black circles represent SNPs being found as lead variants in either Open Targets Genetics or in Ferreira study. Highlighted genes are upregulated upon rhinovirus infection, in purple the genes being L2G genes, in blue the closest one to the transcription start site of the variant (Open Target Genetics), and in black genes found in a window of 250kb around the SNP. The blue dashed line represents the P-value threshold of  $-\log_{10}(5 \times 10^{-8})$ .

**(B)** Box plots depicting gene expression levels for *MYC* (top) and *OVOL1* (bottom). Left panel shows gene expression in epithelial cells from the *Helling et al.* dataset; samples infected with RV-A16 are shown in green and non-infected samples are in brown. Right panel shows gene expression from *Gutierrez-Arcelus et al.* in activated CD4 memory T cells; colors depict time points after activation. In each plot every point represents an individual sample.



# Figure 5



**Figure 5. Influence from other viruses on asthma genetics.**

**(A)** Experimental design of *Tao et al.* bulk RNA-seq dataset.

**(B)** Bar plot representing LDSC-SEG enrichment. Error bars represent  $\tau^*$  +/- standard error. Asterisk denotes significance as \*  $P < 0.05$ .


**(C)** Experimental design of *Ziegler et al.* single-cell RNA-seq dataset of epithelial cells infected with SARS-CoV-2 or not.

**(D)** UMAP visualization of the 32,588 cells colored by cell type.

**(E)** scDRS results represented on the UMAP for the 4 asthma-associated GWAS tested. The intensity of the color represents the disease relevant score, the lighter purple represents a less intense score whereas a more intense purple represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.

**(F)** Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in AOA, COA, Allergy/Eczema and All asthma.

**(G)** Bar plot representing the percentage of cells in the full dataset coming from patients grouped by COVID severity categories (COVID-19, long COVID-19, respiratory failure) or from healthy donors (normal). Followed by percentage of cells passing significance at 10% FDR for AOA, COA, Allergy/Eczema, All asthma, by disease severity category or control.

**Figure 6****Figure 6. Cytokines impact on asthma-associated genes.**

**(A)** Experimental design of the *Koh et al.* bulk RNA-seq dataset of BECs from healthy donors that were stimulated or not with different cytokines (IFN $\gamma$ , IFN $\alpha$ , IL-13, IL-17).


**(B)** Bar plot representing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for genes up-regulated in each stimuli against all others, for each of the asthma-associated GWAS. Error bars represent  $\tau^* \pm$  standard error. NS denotes nonsignificant ( $P > 0.05$ ).

**(C)** Experimental design of bulk RNA-seq of AECs from healthy donors co-stimulated with IL-4 and IL-13.

**(D)** Bar plot showing LDSC-SEG enrichment for each of the asthma-associated GWAS. Error bars represent  $\tau^* \pm$  standard error. NS denotes nonsignificant ( $P > 0.05$ )



# Supplementary Figure 1



## Supplementary Figure 1. Validation of T cells enrichment in asthma-associated loci using differentially accessible peaks.

(A) Experimental design of the *Calderon et al.* ATAC-seq dataset of immune cell types that were activating or not *in vitro*.

(B) Volcano plot showing differentially expressed peaks between T cells and all other cell types. Peaks upregulated in T cells were selected based on t-statistic and are colored in green.


(C) Bar plots representing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for each cell type for the 3 control traits tested.

(D) Bar plot representing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for each set of cell-type-specific differentially accessible peaks for each of the asthma-associated traits.

(E) Bar plots showing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for each of the asthma-associated traits in cell-state-specific DA peaks of immune cells divided in either resting (light colors) or activated (dark colors) condition. In all bar plots, error bars represent  $\tau^* \pm$  standard error and asterisks denote significance as \*\*\* Bonferroni-adjusted  $P < 0.05$ , \*\* FDR 5%, \*  $P < 0.05$ , and NS denotes nonsignificant ( $P > 0.05$ ).



# Supplementary Figure 2



## Supplementary Figure 2. T cell validation at the single-cell RNA-seq level.

**(A)** Experimental design of the *Wang et al.* scRNA-seq dataset of sinonasal mucosa from healthy donors and chronic rhinosinusitis patients (CRS).

**(B)** UMAP visualization of the 1,115,856 immune and non-immune cells colored by cell type.


**(C)** scDRS results represented on the UMAP for the 3 control GWAS tested. The intensity of the color represents the disease relevant score, the lighter purple represents a less intense score whereas a more intense purple represents cells associated with a stronger score. Non-significant cells with a FDR higher than 10% are depicted in gray.

**(D)** Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in Alzheimer's Disease, Height and Rheumatoid Arthritis.

**(E)** scDRS results represented on the UMAP for the 4 asthma-associated traits tested. The intensity of the color represents the disease relevant score, the lighter color represents a less intense score whereas a more intense color represents cells associated with a stronger score.

**(F)** Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in COA, Allergy/Eczema and All asthma.

# Supplementary Figure 3



## Supplementary Figure 3. Th2 validation at the single-cell RNA-seq level.

(A) Experimental design of the *Seumois et al.* scRNA-seq dataset consisting of T cells.


(B) UMAP visualization of the 38,559 T cells colored by subtypes.

(C) scDRS results represented on the UMAP for the 4 asthma-associated GWAS tested. The intensity of the color represents the disease relevant score, the lighter color represents a less intense score whereas a more intense color represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.




# Supplementary Figure 4


**A**



**B**



**C**




## Supplementary Figure 4. Control traits of BECs from healthy individuals infected with RV.

**(A)** Bar plots representing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for the 3 control traits. NS denotes non-significant ( $P > 0.05$ ).

**(B)** Volcano plots showing differentially expressed genes at each time point (12,24,42) compared to all others in RV-infected epithelial cells colored in yellow, orange and brown respectively.

**(C)** Bar plot representing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for each time point against all others for each of the control trait tested. NS denotes non-significant ( $P > 0.05$ ). In all bar plots, error bars represent  $\tau^* \pm$  standard error.

# Supplementary Figure 5



## Supplementary Figure 5. Additional informations related to Figure 2.

UMAP visualization of the 10,721 epithelial cells colored by **(A)** cell type. **(B)** donor.


**(C)** infection status (Infected / Non-infected).

**(D)** Dot plot representing the normalized average expression and the percent of cells expressing a given gene for epithelial cell markers.

**(E)** scDRS results represented on the UMAP for the 3 control GWAS tested. nonsignificant cells with a FDR higher than 10% are depicted in gray.

**(F-I)** Harmonized UMAP representing *CDHR3*, *RVC15*, *LAGLS9* and *SORL1* normalized expressions.

# Supplementary Figure 6




## Supplementary Figure 6. Control traits of BECs from asthma patients infected with RV.

Bar plots representing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for the 3 control traits tested. NS denotes nonsignificant ( $P > 0.05$ ). **(A)** Using DE genes after RV-infection in epithelial cells from patients.

**(B)** Using genes differentially expressed in asthmatics when compared to healthy individuals. **(C)** Bar plot showing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) across traits for genes downregulated upon RVC-15 infection. NS denotes nonsignificant ( $P > 0.05$ ). In all bar plots, error bars represent  $\tau^* \pm$  standard error.




# Supplementary Figure 7



**Supplementary Figure 7. Normalized expressions of gene of interest.**

**(A)** Normalized expression of genes of interest represented on the UMAP and **(B)** on the harmonized UMAP.

# Supplementary Figure 8



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.02.24302068>; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## Supplementary Figure 8. Volcano plot and controls traits related to Figure 5.


**(A)** Volcano plot showing differentially expressed genes between influenza infection and control. Genes upregulated upon influenza infection were selected based on t-statistic and are colored in black.

**(B)** Bar plots representing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for the 3 control GWAS tested. Error bars represent  $\tau^* \pm$  standard error. NS denotes nonsignificant ( $P > 0.05$ ).

**(C)** scDRS results represented on the UMAP for the 3 control traits tested. The intensity of the color represents the disease relevant score, the lighter color represents a less intense score whereas a more intense color represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.



# Supplementary Figure 9



## Supplementary Figure 9. scRNA-seq analysis of BECs infected or not with SARS-CoV-2.

**(A)** Experimental design of the *Ravindra et al.* scRNA-seq dataset of bronchial epithelial cells infected with SARS-CoV-2 or not, from one healthy donor.

UMAP visualization of the 74,088 cells colored by **(B)** days after virus infection and **(C)** by cell type.


**(D)** scDRS results represented on the UMAP for the 3 control traits tested. The intensity of the color represents the disease relevant score, the lighter color represents a less intense score whereas a more intense color represents cells associated with a stronger score. nonsignificant cells with a FDR higher than 10% are depicted in gray.

**(E)** Bar plot representing the percentage of each cell type in all cells followed by the significant cells at 10% FDR for scDRS in AOA, COA, Allergy/Eczema and All Asthma.

**(F)** Bar plot representing the percentage of cells in the full dataset classified in SARS-CoV-2 infection or non infected, followed by percentage of cells passing significance at 10% FDR for AOA, COA, Allergy/Eczema, All asthma, by SARS-CoV-2 infection or not.



# Supplementary Figure 10



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.02.24302068>; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

## Supplementary Figure 10. Control traits for Figure 6.

**(A)** Volcano plots showing differentially expressed genes for each stimuli (IFN $\alpha$ , IFN $\gamma$ , IL-13 and IL-17) compared to all others in bronchial epithelial cells colored in black, teal, orange and brown respectively.

**(B)** Bar plot representing LDSC-SEG enrichment for each stimuli against all others for each of the 3 control traits. Error bars represent  $\tau^* \pm$  standard error. Asterisk denotes significance as \*  $P < 0.05$  and NS denotes nonsignificant ( $P > 0.05$ ).

**(D)** Volcano plot showing differentially expressed genes between IL-4/IL-13 stimulation and resting condition. Genes upregulated upon IL-4/IL-13 stimulation were selected based on t-statistic and are colored in green.

**(E)** Bar plots representing LDSC-SEG heritability enrichment coefficient ( $\tau^*$ ) for the 3 control traits. Error bars represent  $\tau^* \pm$  standard error. Asterisk denotes significance as \*  $P < 0.05$  and NS denotes nonsignificant ( $P > 0.05$ ).